These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12806941)

  • 1. [Bone marrow suppression].
    Urabe A
    Nihon Rinsho; 2003 Jun; 61(6):949-53. PubMed ID: 12806941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [GM-CSF and G-CSF: cytokines in clinical application].
    Ruef C; Coleman DL
    Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
    Repetto L;
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic growth factors as supportive therapy for cancer- and chemotherapy-induced conditions.
    Symann M
    Curr Opin Oncol; 1991 Aug; 3(4):648-55. PubMed ID: 1932223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of erythropoietin alpha in programs of high-dose chemotherapy].
    Danova M; Aglietta M; Pierelli L; Ferrari S; Perillo A; Scambia G; Henry D
    Recenti Prog Med; 2000 Dec; 91(12):681-9. PubMed ID: 11194490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High dose chemotherapy in malignant gliomas using autologous bone marrow transplantation and GM-CSF: granulocyte-macrophage colony stimulating factors].
    Yamashita J; Kawamura T; Shoin K
    No Shinkei Geka; 1990 Apr; 18(4):329-38. PubMed ID: 2197571
    [No Abstract]   [Full Text] [Related]  

  • 9. [A study to overcome drug resistance using high-dose chemotherapy with autologous bone marrow transplantation].
    Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Fukutani H; Tabata M; Hirano A; Mizunuma N; Itami S
    Gan To Kagaku Ryoho; 1989 May; 16(5):2013-8. PubMed ID: 2471462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelotoxicity from chemotherapy.
    Daniel D; Crawford J
    Semin Oncol; 2006 Feb; 33(1):74-85. PubMed ID: 16473646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Palliative therapy in cancer. 5. Side effects by anticancer drugs and their treatments].
    Urushizaki I
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1959-69. PubMed ID: 1697455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic growth factors in cancer chemotherapy.
    Lieschke GJ; Foote M; Morstyn G
    Cancer Chemother Biol Response Modif; 1997; 17():363-89. PubMed ID: 9551221
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy.
    Blumenthal RD; Lew W; Juweid M; Alisauskas R; Ying Z; Goldenberg DM
    Cancer; 2000 Jan; 88(2):333-43. PubMed ID: 10640965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preventing and treating hematologic complications of anticancer chemotherapy: update on hematopoietic growth factors].
    Spaëth D; Geoffrois L; Conroy T
    Bull Cancer; 2000 Jan; 87(1):93-6. PubMed ID: 10673637
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hematopoietic growth factors in primary and therapy-related bone marrow insufficiency].
    Hansen B; Hippe E; Jacobsen GK; Johnsen HE
    Ugeskr Laeger; 1992 Jun; 154(24):1697-702. PubMed ID: 1378668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management and types of side effects in chemotherapy for lung cancer].
    Yoshida K
    Nihon Rinsho; 2002 May; 60 Suppl 5():384-7. PubMed ID: 12101694
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007.
    Wu Y; Aravind S; Ranganathan G; Martin A; Nalysnyk L
    Clin Ther; 2009; 31 Pt 2():2416-32. PubMed ID: 20110050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future strategy for cancer treatment using recombinant human granulocyte colony stimulating factor.
    Diehl V
    Eur J Cancer; 1994; 30A Suppl 3():S44-7. PubMed ID: 7535072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
    Crea F; Giovannetti E; Zinzani PL; Danesi R
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.